Comparison 5. Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Venous thromboembolism end‐of‐treatment	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2 Venous thromboembolism 3‐month follow‐up	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3 Symptomatic deep vein thrombosis end‐of‐treatment	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 Symptomatic deep vein thrombosis 3‐month follow‐up	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
5 Extension of superficial thrombophlebitis 3‐month follow‐up	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
6 Recurrence of superficial thrombophlebitis 3‐month follow‐up	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected